Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
5
Added to
17
Trimmed
9
Exited
6
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $20.55B across 121 positions in their Q4 2021 SEC 13F filing (period ending 2021-12-31). The top 10 positions account for 83.5% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | $7.25B | 35.27% | -0.8% |
| 2 | ONCBeiGene, Ltd. | $3.16B | 15.38% | - |
| 3 | INCYIncyte Corporation | $2.47B | 12.01% | +5.0% |
| 4 | KODKodiak Sciences Inc. | $1.24B | 6.06% | - |
| 5 | ACADACADIA Pharmaceuticals Inc. | $978.20M | 4.76% | - |
| 6 | BMRNBioMarin Pharmaceutical Inc. | $673.27M | 3.28% | - |
| 7 | ASNDUSDAscendis Pharma A/S | $610.98M | 2.97% | - |
| 8 | ARGXargenx SE | $392.06M | 1.91% | - |
| 9 | MRTXEURMirati Therapeutics, Inc. | $206.80M | 1.01% | - |
| 10 | BCRXBioCryst Pharmaceuticals, Inc. | $176.04M | 0.86% | - |
| Stock | Value | Shares |
|---|---|---|
| TRDAEntrada Therapeutics, Inc. | $80.54M | 4,704,419 |
| TSVT*2seventy bio, Inc. | $21.36M | 833,236 |
| SRPTSarepta Therapeutics, Inc. | $11.12M | 123,456 |
| FGENEURFibroGen, Inc. | $8.18M | 580,150 |
| FHTXFoghorn Therapeutics Inc. | $1.03M | 45,027 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.